Vienna, December 20, 2007 -- "Ophthalmological Therapeutics: Pipelines, Delivery Technologies, and Markets," a new market report from H.M. Pharma Consultancy, has been published by our intelligence provider partner, Insight Pharma Reports (www.insightpharmareports.com), a division of Cambridge Healthtech Institute.

"The ocular drug market is a niche market, but it has consistently outperformed the general drug market during the past few years and has tremendous potential because population ageing and the diabetes epidemic will continue to drive the incidence of age-related macular degeneration, retinopathy, and cataract," said report author and H.M. Pharma Consultancy principal Hermann A.M. Mucke, PhD.

"Patenting activity shows very clearly that the small, innovative companies that dominate the ocular drug development scenery are building their strategies on these developments. With our extensive knowledge databases which cover intellectual property as well as the peer-reviewed literature, we are able to give top-level advice to these companies. We might eventually offer these databases as stand-alone products."

The report is available from Insight Pharma Reports as a hardcopy or as a PDF electronic version. A brochure with a table of contents is available at our download page. To order a report, e-mail rlaraia@healthtech.com, call Rose LaRaia at (+1) 781-972-5444, or place a fax order at (+1) 781-972-5425.